Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
about
Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
Enhanced antitumor effects by ...... lumab, an anti-PD-L1 antibody.
@ast
Enhanced antitumor effects by ...... lumab, an anti-PD-L1 antibody.
@en
type
label
Enhanced antitumor effects by ...... lumab, an anti-PD-L1 antibody.
@ast
Enhanced antitumor effects by ...... lumab, an anti-PD-L1 antibody.
@en
prefLabel
Enhanced antitumor effects by ...... lumab, an anti-PD-L1 antibody.
@ast
Enhanced antitumor effects by ...... lumab, an anti-PD-L1 antibody.
@en
P2093
P2860
P356
P1433
P1476
Enhanced antitumor effects by ...... lumab, an anti-PD-L1 antibody.
@en
P2093
Amanda J Vandeveer
Jeffrey Schlom
John W Greiner
Jonathan K Fallon
P2860
P304
20558-20571
P356
10.18632/ONCOTARGET.16137
P407
P577
2017-03-01T00:00:00Z